inotuzumab ozogamicin 0.9 MG Injection [Besponsa]

Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.

Start free with Eleplan

Clinical drug

inotuzumab ozogamicin 0.9 MG Injection [Besponsa]

0.9 MG · Injection · injection

A form of inotuzumab ozogamicin →

inotuzumab ozogamicin 0.9 MG Injection [Besponsa] — CD22 (Clusters of Differentiation 22) inhibitors. Strength, form, class, interactions & more.

inotuzumab ozogamicin 0.9 MG Injection [Besponsa]

Active ingredient

Classification

CD22 (Clusters of Differentiation 22) inhibitorsCD22-directed Immunoconjugate

Drug interactions

Concomitant use of BESPONSA with drugs that prolong the QT interval may increase the risk of QTc interval prolongation.

  • majordrugs that prolong the QT interval — increased risk of clinically significant QTc interval prolongation

Real-world adverse events (FAERS)

Death327Febrile Neutropenia254Venoocclusive Liver Disease253Off Label Use218Pyrexia186Neoplasm Progression155Acute Lymphocytic Leukaemia Recurrent143Thrombocytopenia141

Source: RxNorm + openFDA + RxClass + FAERS · 2026

Look up another medication

Powered by Eleplan

A drug lookup is just the start. Eleplan keeps the whole care plan in one place.

Medications, diagnoses, documents, appointments, and the whole care team — organized and always in sync, with Ellie, your AI care assistant, on top of it. Free to start.